GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Cyclically Adjusted PB Ratio

Alimera Sciences (Alimera Sciences) Cyclically Adjusted PB Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alimera Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alimera Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Cyclically Adjusted PB Ratio Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alimera Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alimera Sciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alimera Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Cyclically Adjusted PB Ratio falls into.



Alimera Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alimera Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Alimera Sciences's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.882/129.4194*129.4194
=0.882

Current CPI (Dec. 2023) = 129.4194.

Alimera Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201403 -8.437 99.695 -10.953
201406 -5.049 100.560 -6.498
201409 -3.728 100.428 -4.804
201412 -6.524 99.070 -8.523
201503 -9.538 99.621 -12.391
201506 -11.980 100.684 -15.399
201509 -11.952 100.392 -15.408
201512 -14.156 99.792 -18.359
201603 -17.298 100.470 -22.282
201606 -18.840 101.688 -23.978
201609 -8.985 101.861 -11.416
201612 -9.992 101.863 -12.695
201703 -11.269 102.862 -14.178
201706 -10.537 103.349 -13.195
201709 -10.426 104.136 -12.957
201712 -11.687 104.011 -14.542
201803 -12.912 105.290 -15.871
201806 -13.548 106.317 -16.492
201809 -5.862 106.507 -7.123
201812 -5.912 105.998 -7.218
201903 -6.277 107.251 -7.574
201906 -7.189 108.070 -8.609
201909 -7.777 108.329 -9.291
201912 -7.006 108.420 -8.363
202003 -7.109 108.902 -8.448
202006 -7.527 108.767 -8.956
202009 -7.080 109.815 -8.344
202012 -4.757 109.897 -5.602
202103 -5.421 111.754 -6.278
202106 -1.926 114.631 -2.174
202109 -2.559 115.734 -2.862
202112 -3.148 117.630 -3.464
202203 -3.980 121.301 -4.246
202206 -4.512 125.017 -4.671
202209 -5.331 125.227 -5.509
202212 -5.723 125.222 -5.915
202303 -3.605 127.348 -3.664
202306 -3.237 128.729 -3.254
202309 0.932 129.860 0.929
202312 0.882 129.419 0.882

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alimera Sciences  (NAS:ALIM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alimera Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alimera Sciences (Alimera Sciences) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Executives
Margaret Pax director 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko director C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont director 51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers other: Chairman Emeritus 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan director 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman 10 percent owner FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076